LongevityRx Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

A GLP-1 company can document a service without demonstrating how well its own treatment works. That distinction is central to LongevityRx, which advertises compounded injectable semaglutide starting at $149 per month and compounded injectable tirzepatide starting at $169 per month. Its pages describe clinician review, pharmacy preparation, home delivery and follow-up. Those are meaningful service claims, but they do not establish the effectiveness of its formulations, the performance of its clinicians or the results a particular patient should expect.

This review examines public documentation consulted October 19, 2026, separating commercial promises, contractual responsibilities and clinical evidence. LongevityRx provides more detail than a simple medication advertisement, including recurring-payment terms and pharmacy-channel restrictions. Yet its documents also disagree on cancellation deadlines and present different descriptions of clinical identity and privacy. The practical question is not simply whether GLP-1 medicines have research behind them; it is which parts of that research, and which service promises, actually apply to this offering.

At a glance

Advertised injectable prices: Compounded semaglutide injection starts at $149/month; compounded tirzepatide injection starts at $169/month. Starting prices are not established as universal or permanent rates.
Sources: [6] [7]
Platform and clinical responsibility: Cal Choice Family Practice, Inc owns and operates the site. Its terms say it does not provide clinical care, prepare or dispense medicines, or control independent providers’ professional judgment.
Sources: [8]
Recurring billing: For recurring monthly orders, the terms authorize an immediate charge and subsequent charges every 30 days until cancellation, with electronic notice five to seven days before a scheduled transaction.
Sources: [8]
Conflicting cancellation deadlines: Treatment FAQs require 30 days’ notice before the next billing cycle; the terms allow auto-refill cancellation in the portal up to 48 hours before monthly processing.
Sources: [7] [8]
Compounding evidence boundary: LongevityRx acknowledges that compounded medicines are not FDA approved. FDA recommends compounded drugs when an individual’s medical needs cannot be met by an approved drug.
Sources: [6] [1]

Start with the product, not the research headline

LongevityRx’s principal weight-management offerings are compounded semaglutide injection and compounded tirzepatide injection. Treatment pages say partner compounding pharmacies prepare the medication and ship it on a structured cadence, without establishing the supply interval or quantity associated with each payment. The homepage also promotes peptides for recovery, metabolism, longevity and focus, described as reviewed by a licensed provider and compounded in a U.S. pharmacy. These are descriptions of available services, not evidence that every advertised purpose has been demonstrated.

Its separate GLP-1 Microdose program is presented as a lower-dose protocol for metabolic health, body composition and appetite recalibration rather than aggressive weight loss. Advertised candidates include people at or near their goal weight and people who tolerated standard GLP-1 protocols poorly. However, the consulted documentation does not specify the program’s active ingredient or route. Without those basics, a reader cannot reliably connect its marketing to research on a particular medicine, formulation or treatment regimen.

The site acknowledges that compounded medicines are not FDA approved and that FDA has not independently verified their safety, effectiveness and quality. FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Nonapproval alone does not demonstrate clinical inequivalence, but neither does a familiar ingredient name establish equivalent evidence. Our guide to approved medicines and compounded preparations explains why those are separate questions.

What the advertised offerings establish
Offering or claim	Documented detail	Evidence boundary
Semaglutide injection	Compounded program starting at $149/month	Supply quantity and provider-specific outcomes are not established
Tirzepatide injection	Compounded program starting at $169/month	Starting-price eligibility and duration are not explained
GLP-1 Microdose	Lower-dose program marketed for metabolic health and body composition	Active ingredient, route and demonstrated program benefits are not established
Other peptides	Provider-reviewed therapies compounded in a U.S. pharmacy	Specific formulations and routes are not established
Ongoing care	Portal messaging and check-ins are advertised	A minimum consultation frequency is not specified

Sources: [6] [7] [5] [1]

Clinical trials do not measure LongevityRx’s performance

Research on semaglutide and tirzepatide can explain why these medicines attract interest, but it cannot function as a report card for LongevityRx. STEP 1 studied subcutaneous semaglutide in adults with obesity or overweight plus a weight-related condition, without diabetes, over 68 weeks. Both groups received lifestyle intervention. It did not study this platform, its partner pharmacies or its compounded preparations. Our STEP 1 evidence guide explains how to keep that distinction intact when reading treatment advertising.

SURMOUNT-1 likewise studied a defined intervention: subcutaneous tirzepatide in adults with obesity or overweight plus a weight-related complication, excluding diabetes, over 72 weeks. It was not a trial of LongevityRx or its Microdose program. Both trials reported gastrointestinal tolerability concerns; STEP 1 was funded by Novo Nordisk and SURMOUNT-1 by Eli Lilly. Their findings should not be converted into predicted individual results or a head-to-head ranking based on separate studies. The SURMOUNT-1 reading guide provides additional context.

For LongevityRx specifically, the consulted documentation does not establish measured treatment outcomes, adherence, treatment discontinuation or adverse-event rates. That does not prove poor performance; it means performance remains unverified here. The distinction is especially important for the Microdose offering, whose advertised population and intended goals differ from the populations and regimens described above. A provider’s use of clinical research should be evaluated for relevance to the actual product and service, not merely for whether a recognizable study appears nearby.

Sources: [3] [4] [5] [7]

Who is actually responsible for the care?

The terms identify Cal Choice Family Practice, Inc as the website’s owner and operator. The homepage disclaimer calls LongevityRx a concierge telehealth platform connecting patients with independent clinical providers, described by the site as U.S. board-certified, and state-licensed compounding pharmacies. Those credentials are provider claims, not independently verified findings in this review. The terms explicitly say the operator does not practice medicine, provide clinical care, prepare or dispense medication, or control a provider’s or pharmacy’s professional judgment.

Treatment pages use a different description: a physician-led practice powered by board-certified physicians and licensed clinicians specializing in GLP-1 weight loss, peptides and longevity medicine. A platform can coordinate access to clinical services, but these descriptions leave the patient needing a clearer map of responsibility. The consulted documentation does not identify treating professionals, their medical groups or partner pharmacies by name. It therefore does not allow this review to verify individual licenses, certifications or the entity responsible for a particular consultation.

Enrollment begins with a short online assessment covering health goals and basic medical history. A licensed clinician reviews the information and, if clinically appropriate, develops a personalized plan and coordinates care. Treatment is not guaranteed, and clinical decisions belong to licensed providers. Access also requires a registered account with a username and password. Before authorizing payment, a useful request is the name and credentials of the treating clinician, the medical group providing care and the pharmacy expected to fill any prescription.

Sources: [8] [6] [7]

Read the starting price alongside the recurring charge

The homepage advertises semaglutide injection from $149 per month and tirzepatide injection from $169 per month, including an online provider visit, prescription, discreet home delivery and ongoing care and check-ins. It also displays $249 and $299 respectively, without explaining their commercial role in the consulted text. Those figures should not automatically be labeled regular renewal prices or compared as a documented discount. The site says plans from $149 per month are confirmed after provider review and labels the estimate educational.

Treatment pages promise flat-rate pricing, no hidden fees, no consultation charges and no dose-change surcharges. The terms describe a bundled subscription price encompassing the pharmacy’s prescription-drug fee, the medical group’s clinical-service fee and the platform-access charge. The homepage also says the preliminary assessment has no obligation and costs $0 if the applicant is not approved. These statements are useful, but they do not establish what quantity of medicine accompanies a charge, whether laboratory testing is required or whether testing costs are included.

For recurring monthly orders, the terms authorize charging immediately and every 30 days thereafter until cancellation, with electronic notice five to seven days before a transaction and a receipt afterward. A 30-day interval is not identical to calendar-month billing. The homepage markets pricing without insurance, but that does not establish a full reimbursement policy. Starting-rate duration, taxes, financing, HSA/FSA use, minimum commitments and any prepayment discounts remain unestablished; readers should obtain an itemized offer rather than infer those terms from “flat-rate” language.

Sources: [6] [7] [8]

Cancellation has two published deadlines

The most consequential contractual discrepancy concerns ending a subscription. Treatment FAQs say memberships may be canceled with 30 days’ notice before the next billing cycle. The terms instead allow cancellation by turning off auto-refill in the user portal up to 48 hours before the applicable monthly processing date. These are materially different deadlines. A patient relying on one could reasonably reach a different conclusion about whether another charge will occur, so neither should be silently treated as the sole rule.

The treatment pages separately state that consultations, medical visits and fulfilled prescriptions are nonrefundable once services begin or medication is processed. Stopping future renewal is therefore not the same as receiving money back for work already started or a prescription already processed. The advertised $0 charge for applicants who are not approved should also be kept separate from this later-stage refund boundary. It is not documentation of a general satisfaction guarantee or a right to return dispensed medication.

Before enrolling, ask which cancellation provision governs the selected program, what date counts as monthly processing and how cancellation is confirmed. Keeping the written response and portal confirmation would make the arrangement clearer, but this review cannot determine which conflicting provision the company would apply in a dispute. The full checkout process and patient portal were not reviewed, and the consulted terms text omitted an intermediate section. That limits conclusions about the complete enrollment agreement and any additional conditions presented before purchase.

Sources: [6] [7] [8]

Eligibility and nationwide advertising need a closer reading

LongevityRx advertises nationwide telehealth, but its terms limit service to states where the operator operates. They also require patients to be at least 18, or the local age of majority if higher, and physically located in the same state as the shipping address when consulting a provider. No state-by-state or product-specific availability list was established in the consulted documentation. Someone traveling, using a temporary address or seeking a particular program should confirm the applicable location requirements before assuming access.

The semaglutide page advertises candidates as adults 18 or older with a BMI of at least 27, or at least 25 with weight-related conditions. Its published exclusions include personal or family history of medullary thyroid carcinoma or MEN 2; pregnancy, breastfeeding or pregnancy planning; active pancreatitis; and untreated severe gastrointestinal disease. These are the provider’s published criteria, not individualized eligibility advice or a complete clinical screening. The tirzepatide page additionally markets supervised switching for patients who have plateaued on a single-agonist GLP-1.

These advertised thresholds should not be confused with general clinical guidance. NIDDK describes general adult pharmacotherapy thresholds of BMI 30 or higher, or 27 or higher with weight-related health problems, while emphasizing broader clinical assessment. LongevityRx’s lower advertised thresholds therefore warrant a specific explanation from the treating clinician. NIDDK also recommends discussing other medicines, supplements, allergies and pregnancy plans. An online eligibility statement cannot substitute for that conversation, and approval to use the platform does not guarantee that a prescription will be appropriate.

Sources: [6] [7] [11] [8] [2]

Pharmacy, delivery and follow-up are separate responsibilities

The terms require prescriptions obtained through an included service to be filled through a pharmacy accessible on the platform, and state that the purchaser waives choosing another pharmacy for that prescription. The applicable pharmacy ships directly to the patient. The terms also warn that prescription products will not be dispensed in child-resistant containers. These are concrete service restrictions worth understanding before purchase, particularly because the consulted documentation does not name the partner pharmacies or establish the exact presentation and quantity to be supplied.

Treatment pages advertise temperature-controlled, unmarked delivery packaging; the homepage advertises free two-to-three-day shipping. That shipping claim does not establish total time from assessment to arrival, because clinical review and pharmacy preparation are separate steps. Policies for loss, delays or temperature problems were not established. FDA explicitly recommends not using an injectable GLP-1 product that arrives warm or inadequately refrigerated and contacting the provider or dispensing pharmacy. Advertising temperature control is not a substitute for a clear process when a shipment raises concerns.

For ongoing care, LongevityRx advertises direct messaging with the provider through a secure portal between scheduled check-ins. The homepage says follow-ups occur as needed, but no minimum visit frequency, response-time commitment for clinician messages or laboratory schedule is established. NIDDK describes follow-up as monitoring tolerance and response, not merely renewing payment. Our guide to clinical follow-up questions helps distinguish accessible messaging from a defined monitoring plan. Ask who reviews concerns, how quickly and what happens outside published clinical hours.

Sources: [8] [7] [6] [1] [2]

Privacy promises and contact routes deserve verification

The treatment FAQ says LongevityRx is HIPAA compliant, shares medical information only with the assigned provider and dispensing pharmacy, and never sells or shares data. The terms give a more qualified account: the operator says it is not a HIPAA covered entity and may act as a business associate of a pharmacy or medical group in certain circumstances. Those categories are not interchangeable. The full HIPAA notice was not reviewed, so this review cannot resolve the handling of every category of information.

The California privacy notice adds that certain personal information may be made available to third parties for advertising measurement, improvement and relevant offers, and that those disclosures may qualify as a sale or sharing under California law. That materially qualifies the broad FAQ language without establishing that every medical record is used for advertising. Before submitting sensitive information, readers should clarify which policy applies to intake data, account activity and medical information, and how to exercise any available privacy choices.

The contact page lists support@startlongevityrx.com and (760) 493-6185, with clinical hours Monday through Friday, 9 a.m. to 5 p.m.; the displayed block does not specify a time zone. Its form promises a team response within 24 hours, not clinical approval or medication delivery within that period. The California notice displays a different placeholder-style phone number, making the published support channels more practical starting points for confirming a valid privacy contact. English-language pages do not establish Spanish-language care or interpretation availability.

Sources: [10] [7] [8] [9]

Questions & answers

Are $149 and $169 guaranteed ongoing prices?

No such guarantee is established. LongevityRx advertises compounded semaglutide injection from $149/month and compounded tirzepatide injection from $169/month. The homepage says pricing is confirmed after provider review. It does not explain starting-rate duration, supply quantity or the role of the additional displayed $249 and $299 figures. Request the actual recurring charge before enrolling.

Sources: [6]

Can I take the prescription to my preferred pharmacy?

The terms restrict this. A prescription included in a purchased service is filled through a pharmacy accessible through the platform, and the purchaser agrees to waive choosing another pharmacy for that prescription. Because partner pharmacies are not named in the consulted documentation, ask for the dispensing pharmacy’s identity before agreeing to the service.

Sources: [8]

How much notice does LongevityRx require to cancel?

Its documents give two answers: treatment FAQs require 30 days before the next billing cycle, while the terms allow disabling auto-refill up to 48 hours before monthly processing. Obtain written clarification for your program rather than assuming the shorter deadline applies. Cancellation also does not establish a refund for services begun or medication processed.

Sources: [7] [8]

Does the Microdose program have the same evidence as standard GLP-1 treatment?

The consulted documentation does not establish that. LongevityRx describes a lower-dose program with different goals and advertised candidates, but does not specify its active ingredient or route. STEP 1 and SURMOUNT-1 studied defined regimens and populations, not this program. Their findings cannot establish Microdose benefits, tolerability or expected individual outcomes.

Sources: [5] [3] [4]

Does free two-to-three-day shipping mean treatment arrives that quickly?

Not necessarily. The claim concerns shipping, not the complete interval from assessment through clinical review, pharmacy preparation and arrival. Those earlier timelines are not established. If an injectable GLP-1 shipment arrives warm or inadequately refrigerated, FDA advises not using it and contacting the provider or dispensing pharmacy to resolve the concern.

Sources: [6] [1]

How can I reach someone before paying?

The contact page lists support@startlongevityrx.com and (760) 493-6185. It gives weekday clinical hours of 9 a.m. to 5 p.m. without specifying a time zone, and promises a response to its contact form within 24 hours. Use that opportunity to confirm state availability, the treating entity, pharmacy identity, cancellation terms and your complete quoted price.

Sources: [10] [8]

Our assessment

LongevityRx documents a recognizable telehealth offering: compounded injectable GLP-1 programs, clinician review, bundled pricing claims, pharmacy delivery and portal follow-up. Its acknowledgment of compounding’s FDA status is useful, as are its published recurring-payment and pharmacy-channel terms. The limits are equally material. Public documentation does not establish provider-specific clinical outcomes, named treating professionals or pharmacies, precise supply quantities or a defined monitoring schedule. Conflicting cancellation deadlines and qualified privacy language deserve written clarification before enrollment. The strongest basis for evaluating this service is therefore its actual individualized offer and assignment of responsibilities—not trial percentages associated with the medicine names. Readers should leave a pre-enrollment inquiry with a confirmed price, dispensing pharmacy, clinical contact and applicable cancellation deadline.

Visit LongevityRx’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

LongevityRx Review: What Its GLP-1 Documentation Establishes—and What It Doesn’t

At a glance

01Start with the product, not the research headline

02Clinical trials do not measure LongevityRx’s performance

03Who is actually responsible for the care?

04Read the starting price alongside the recurring charge

05Cancellation has two published deadlines

06Eligibility and nationwide advertising need a closer reading

07Pharmacy, delivery and follow-up are separate responsibilities

08Privacy promises and contact routes deserve verification